article

Psilocybin, the psychoactive compound from magic mushrooms, is being used to treat depression and anxiety in terminally ill patients in a new trial at Melbourne’s St Vincent’s Hospital.

Prestigious international institutions have initiated robust psychedelic research programs. Does Australia risk being left behind if it doesn’t do the same?

New research published in the Australian Psychologist Journal claims Australia is missing out on the benefits of using psychedelic drugs to treat a range of mental health illnesses.

Australia is missing out on a global “renaissance” of research into use of psychedelic drugs to treat mental health problems, two psychologists say.

PRISM President Dr Martin Williams talks with ABC Radio’s Beyond the Lab about the Psychedelic Renaissance.

In a press release dated 26 August 2017, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the US Food and Drug Administration has granted ‘Breakthrough [...]

Scientists believe the illegal drug MDMA, also known as ecstasy, has an untapped potential to treat post-traumatic stress disorder (PTSD). But they say plans to test the drug on war veterans in [...]

PRISM is a proud sponsor of the Entheogenesis Australis 2017 Outdoor Psychedelic Symposium. For over a decade Entheogenesis Australis has provided a major meeting place for ethnobotanical [...]

PRISM Vice President Dr Stephen Bright reflects on his attendance as a guest speaker at Beyond Psychedelics 2016 in Prague.

Dr Stephen Bright talks to The Psychedelia Podcast about the problems facing the psychedelic movement in Australia

Dr Stephen Bright, a Psychologist working at Curtin University discusses psychedelic therapy.

Paul Gregoire from Sydney Criminal Lawyers spoke with PRISM’s Dr Stephen Bright about treating PTSD with MDMA-assisted therapy.

Dr Martin Williams, president of Psychedelic Research in Science & Medicine talks on ABC Radio Alice Springs

MDMA — more commonly known as ecstasy — is one step closer to becoming a legal form of treatment for post-traumatic stress disorder (PTSD) in the United States.

In September 2016 PRISM’s Vice President Dr Stephen Bright spoke at Beyond Psychedelics, a global multidisciplinary psychedelic forum held in Prague, Czech Republic.

Could returned servicemen with war-ravaged hearts and minds soon be given MDMA to smooth their way back into society?

A recent review in Pharmacological Reviews highlights that over the last decade, a renaissance has occurred in psychedelic drug research

UK psychiatrist Dr Ben Sessa talks about MDMA’s application in psychiatry, at TEDx University of Bristol.

When Martin Williams’ research plan was first rejected by an ethics committee in 2012, he understood why. The medicinal chemistry researcher could see some valid sticking points.

Click here to listen: https://soundcloud.com/enpsychedelia/the-psychedelic-inquirer-prism-interview

Some drugs that have therapeutic benefits are banned because of emerging patterns of use that do not conform to dominant paradigms. Such policies are often driven by morality rather than evidence.

ABC Radio National’s program The Drawing Room recently interviewed PRISM’s Steve McDonald and Ridiculusmus Artistic Director David Woods about MDMA-therapy to treat posttraumatic stress

In April 2014 PRISM’s President Martin Williams and Vice President Stephen Bright were invited to join a panel discussion at the Melbourne screening of Neurons to Nirvana,

As UK researchers begin human therapeutic experiments using the psychedelic drug LSD an Australian group are setting up the nation’s first clinical study using MDMA